- Home
- / Effector Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Effector Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-10-29
Market Capitalization
$1.9 K
2024-10-29
Revenue
$3.6 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|
| Revenue | 1.4M | 3.6M | |
| General and administrative expense | 13.4M | 12.6M | 10.9M |
| Operating expense total | 33.3M | 36.0M | |
| EBIT | (31.9M) | (32.4M) | (33.8M) |
| EBIT margin, % | -2230.6% | -912.0% | |
| Interest income | 6.0K | 439.0K | 972.0K |
| Interest expense | 1.8M | 2.3M | 2.9M |
| Pre tax profit | 15.8M | ||
| Net Income | 15.8M | (22.7M) | (35.8M) |
| EPS | 0.4 | (0.5) | (16.0) |